OTC : DSKYF

Daiichi Sankyo Company, Limited

$15.81 USD

-$0.19 (-1.19%)

Volume
750
Average Volume
11.86K
Market Capitalization
$28.77B
P/E Ratio
19.88
Dividend Yield
2.79%
Price Target
Year High
$29.15
Year Low
$13.85
Day High
—
Day Low
—
Payout Ratio
$0.49
Current Ratio
$2.42
Company Overview

OTC

Hiroyuki Okuzawa

Drug Manufacturers - General

Healthcare

DSKYF

20171

JP

USD

https://www.daiichisankyo.com

81 3 6225 1111

N/A

N/A

Liquidity Metrics

0.18

2.42

1.64

0.51

0.49

Sales & Valuation

$2.14T

2.39

3.08

-100.15

-27.61

Profitability

$140.61

$261.51B

12.24%

12.41%

15.74%

6.49%

P/E Metrics

19.88

-2.01

-2.01

Analyst Price Target & Rating

Neutral

3/5

0 Analysts

%

Poll Results

About Daiichi Sankyo Company, Limited (OTC:DSKYF) Stock

Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products. The company boasts an extensive portfolio of therapeutics spanning numerous health conditions. In oncology, its offerings include trastuzumab deruxtecan, an innovative anti-HER2 antibody-drug conjugate for cancer treatment, alongside agents such as gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen for breast cancer. For chronic diseases, Daiichi Sankyo provides mirogabalin for pain management; treatments for type 2 diabetes mellitus like teneligliptin/canagliflozin and teneligliptin; and medications for hypercholesterolemia, including pravastatin and colesev ... elam (which also addresses type 2 diabetes). Bone health is supported by denosumab for osteoporosis and related conditions, while anemia is managed with ferric carboxymaltose and iron sucrose injections. Its cardiovascular and neurological solutions include the antiplatelet agent prasugrel, the anticoagulant edoxaban, and the antihypertensive olmesartan; as well as lacosamide for epilepsy and memantine for Alzheimer's disease. Other key prescription products address conditions such as ulcers (esomeprazole), influenza (laninamivir), bacterial infections (levofloxacin), dysuria (silodosin), and general pain and inflammation (loxoprofen). Beyond prescription drugs, Daiichi Sankyo also markets a selection of consumer health items. These comprise the multi-symptom cold remedy Lulu, the antipyretic/anti-inflammatory pain reliever Loxonin S, Transino for skin discoloration like melasma and freckles, Minon skincare products, and the oral hygiene brands Breath Labo and Clean Dental. Furthermore, the company produces various vaccines, including those for influenza (both cell culture-derived and HA types), measles, rubella, and mumps. Its diverse operations extend to veterinary pharmaceuticals, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and chemical intermediates. A significant collaboration involves Guardant Health, with whom Daiichi Sankyo is developing Guardant360 CDx as a companion diagnostic for Enhertu, specifically targeting advanced metastatic non-small cell lung cancer. Established in 1899, this long-standing organization is headquartered in Tokyo, Japan.

Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript

2026-05-11 16:20:44

Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Daiichi Sankyo Company, Limited (DSKYF) stock price?

Daiichi Sankyo Company, Limited(OTC:DSKYF) stock price is $15.81 in the last trading session. During the trading session, DSKYF stock reached the peak price of $29.15 while $13.85 was the lowest point it dropped to. The percentage change in DSKYF stock occurred in the recent session was --1.19% while the dollar amount for the price change in DSKYF stock was -$0.19.

DSKYF's industry and sector of operation?

The OTC listed DSKYF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of DSKYF?

Stuart Mackey | Global Head of Business Development & Director
Tetsuya Ohira | Corporate Officer, Head of Business Transformation & CTO
Thierry Gruson | Head of Global Oncology Marketing
Sunao Manabe | Executive Chairperson
Joseph Kenneth Keller | Head of Oncology Business Unit & Global Oncology Business and Director

How many employees does DSKYF have?

Number of DSKYF employees currently stands at 20171. DSKYF operates from 3-5-1, Nihonbashi-honcho, Tokyo, TY 103-8426, JP.

Link for DSKYF official website?

Official Website of DSKYF is: https://www.daiichisankyo.com

How do I contact DSKYF?

DSKYF could be contacted at phone #81 3 6225 1111 and can also be accessed through its website. DSKYF operates from 3-5-1, Nihonbashi-honcho, Tokyo, TY 103-8426, JP.

How many shares of DSKYF are traded daily?

The average number of DSKYF shares traded daily for last 3 months was 11.86K.

What is the market cap of DSKYF currently?

The market value of DSKYF currently stands at $28.77B with its latest stock price at $15.81